![](https://medcitynews.com/uploads/2021/07/GettyImages-1280895783-150x150.jpg)
PAREXEL
-
While Auto vs. Allo Cell Therapy Debate Continues, VCs Look for ‘Next Shiny Thing’
Allogeneic cell therapy hasn’t caught up to autologous cell therapy yet, and the disappointing data so far has soured the entire allogeneic field for at least one venture capitalist. The cell therapy debate was one of the topics covered during a panel discussion at the Biopharm America conference.
-
What’s coming up at MedCity INVEST Precision Medicine Day 3?
The final day of the conference, Friday, December 11, includes a panel on precision medicine investment trends, a look at clinical trial design innovation and the life sciences track of our Pitch Perfect startup contest. Register now!
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Parexel, Datavant partner on using real-world data in clinical trials
Parexel, one of the largest CROs in the world, said the partnership would involve connecting real-world data across the clinical trials it conducts.
-
Could automating raw materials production bring down gene therapy prices?
Experts at last week’s BIO meeting in Philadelphia discussed the long-term implications of many gene therapies hitting the market, and ways their prices could be lowered so they’d be more cost-effective.
-
Global CRO market to grow to $57 billion by 2024, report forecasts
Growth in the CRO sector is expected to accompany growth of clinical trials, their complexity and regulatory requirements.